ITeos Therapeutics Analyst Ratings
ITeos Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/09/2023 | 261.54% | HC Wainwright & Co. | $54 → $44 | Maintains | Buy |
03/17/2023 | 343.71% | HC Wainwright & Co. | → $54 | Reiterates | → Buy |
03/16/2023 | 162.94% | JP Morgan | $34 → $32 | Maintains | Overweight |
03/16/2023 | 171.16% | Wedbush | $45 → $33 | Maintains | Outperform |
05/13/2022 | 384.8% | SVB Leerink | $60 → $59 | Maintains | Outperform |
12/13/2021 | 343.71% | HC Wainwright & Co. | $37 → $54 | Maintains | Buy |
11/12/2021 | 343.71% | SVB Leerink | $55 → $54 | Maintains | Outperform |
08/13/2021 | 351.93% | SVB Leerink | $56 → $55 | Maintains | Outperform |
05/19/2021 | 269.76% | SVB Leerink | $60 → $45 | Maintains | Outperform |
05/05/2021 | 204.03% | HC Wainwright & Co. | → $37 | Initiates Coverage On | → Buy |
04/06/2021 | 393.02% | SVB Leerink | $37 → $60 | Maintains | Outperform |
11/19/2020 | 204.03% | SVB Leerink | $36 → $37 | Maintains | Outperform |
10/08/2020 | 269.76% | Baird | → $45 | Initiates Coverage On | → Outperform |
08/18/2020 | 228.68% | JP Morgan | → $40 | Initiates Coverage On | → Overweight |
08/18/2020 | 269.76% | Wedbush | → $45 | Initiates Coverage On | → Outperform |
08/18/2020 | 195.81% | SVB Leerink | → $36 | Initiates Coverage On | → Outperform |
08/18/2020 | 310.85% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
08/09/2023 | 261.54% | HC Wainwright & Co. | 54 美元 → 44 美元 | 维护 | 购买 |
03/17/2023 | 343.71% | HC Wainwright & Co. | → 54 美元 | 重申 | → 购买 |
03/16/2023 | 162.94% | 摩根大通 | 34 美元 → 32 美元 | 维护 | 超重 |
03/16/2023 | 171.16% | Wedbush | 45 美元 → 33 美元 | 维护 | 跑赢大盘 |
05/13/2022 | 384.8% | SVB Leerink | 60 美元 → 59 美元 | 维护 | 跑赢大盘 |
2021 年 12 月 13 日 | 343.71% | HC Wainwright & Co. | 37 美元 → 54 美元 | 维护 | 购买 |
11/12/2021 | 343.71% | SVB Leerink | 55 美元 → 54 美元 | 维护 | 跑赢大盘 |
08/13/2021 | 351.93% | SVB Leerink | 56 美元 → 55 美元 | 维护 | 跑赢大盘 |
2021 年 5 月 19 日 | 269.76% | SVB Leerink | 60 美元 → 45 美元 | 维护 | 跑赢大盘 |
2021 年 5 月 5 日 | 204.03% | HC Wainwright & Co. | → 37 美元 | 启动覆盖开启 | → 购买 |
04/06/2021 | 393.02% | SVB Leerink | 37 美元 → 60 美元 | 维护 | 跑赢大盘 |
2020 年 11 月 19 日 | 204.03% | SVB Leerink | 36 美元 → 37 美元 | 维护 | 跑赢大盘 |
2020 年 8 月 10 日 | 269.76% | 贝尔德 | → 45 美元 | 启动覆盖开启 | → 跑赢大盘 |
08/18/2020 | 228.68% | 摩根大通 | → 40 美元 | 启动覆盖开启 | → 超重 |
08/18/2020 | 269.76% | Wedbush | → 45 美元 | 启动覆盖开启 | → 跑赢大盘 |
08/18/2020 | 195.81% | SVB Leerink | → 36 美元 | 启动覆盖开启 | → 跑赢大盘 |
08/18/2020 | 310.85% | 派珀·桑德勒 | → 50 美元 | 启动覆盖开启 | → 超重 |
What is the target price for ITeos Therapeutics (ITOS)?
iTEOS Therapeutics(ITOS)的目标价格是多少?
The latest price target for ITeos Therapeutics (NASDAQ: ITOS) was reported by HC Wainwright & Co. on August 9, 2023. The analyst firm set a price target for $44.00 expecting ITOS to rise to within 12 months (a possible 261.54% upside). 4 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年8月9日公布了iTeOS Therapeutics(纳斯达克股票代码:ITOS)的最新目标股价。该分析公司将目标股价定为44.00美元,预计ITOS将在12个月内上涨至261.54%(可能上涨261.54%)。去年有4家分析公司公布了评级。
What is the most recent analyst rating for ITeos Therapeutics (ITOS)?
iTEOS Therapeutics(ITOS)的最新分析师评级是多少?
The latest analyst rating for ITeos Therapeutics (NASDAQ: ITOS) was provided by HC Wainwright & Co., and ITeos Therapeutics maintained their buy rating.
iTeOS Therapeutics(纳斯达克股票代码:ITOS)的最新分析师评级由HC Wainwright & Co. 提供,iTeOS Therapeutics维持买入评级。
When is the next analyst rating going to be posted or updated for ITeos Therapeutics (ITOS)?
iTEOS Therapeutics(ITOS)的下一次分析师评级何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ITeos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ITeos Therapeutics was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析师在进行了广泛的研究后得出了股票评级,包括阅读公开财务报表、与iTeos Therapeutics的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级,因此每家公司每年应获得4个评级。iTeOS Therapeutics的最后一次评级是在2023年8月9日提交的,因此你应该预计下一个评级将在2024年8月9日左右公布。
Is the Analyst Rating ITeos Therapeutics (ITOS) correct?
分析师对iTEOS Therapeutics(ITOS)的评级是否正确?
While ratings are subjective and will change, the latest ITeos Therapeutics (ITOS) rating was a maintained with a price target of $54.00 to $44.00. The current price ITeos Therapeutics (ITOS) is trading at is $12.17, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的iTEOS Therapeutics(ITOS)评级保持不变,目标股价为54.00美元至44.00美元。iTEOS Therapeutics(ITOS)目前的交易价格为12.17美元,超出了分析师的预测区间。